Cardiogeni (AQSE:CGNI) Research & Development: £ Mil (TTM As of . 20)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Cardiogeni Research & Development?

Cardiogeni AQSE:CGNI Research & Development is £ Mil as of . 20.

Research & Development is the aggregate amount of research and development expenses during the year. Cardiogeni's Research & Development for the six months ended in . 20 was £0.00 Mil. Cardiogeni does not have enough years/quarters to calculate the Research & Development for the trailing twelve months (TTM) ended in . 20.

Cardiogeni  (AQSE:CGNI) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Cardiogeni Research & Development Related Terms

Cardiogeni Research & Development Historical Data

* Premium members only.

The historical data trend for Cardiogeni's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cardiogeni Research & Development Chart

Cardiogeni Annual Data
Trend
Research & Development

Cardiogeni Semi-Annual Data
Research & Development

Cardiogeni Research & Development Calculation

This is the expense the company spent on research and development.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of £ Mil mean?
Cardiogeni (AQSE:CGNI) has a Research & Development of £ Mil as of . 20. Research and development expense is the total cost for research and development activities. View historical data on Cardiogeni and its competitors.
Is Cardiogeni's Research & Development too high?
Cardiogeni's current Research & Development is £ Mil.
How does Cardiogeni's Research & Development compare to ?
Cardiogeni's Research & Development of £ Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Biotechnology company?
A good Research & Development depends on the Biotechnology industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Cardiogeni and its competitors. Cardiogeni's current Research & Development is £ Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cardiogeni stock overvalued right now?
Cardiogeni (AQSE:CGNI) has a current Research & Development of £ Mil. The current Research & Development is £ Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Cardiogeni (AQSE:CGNI), the current Research & Development is £ Mil as of . 20. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Cardiogeni Business Description

Comparable Companies
Address Celixir House Stratford-Upon-Avon Business & Technology Park, Innovation Way, Stratford upon Avon, GBR, CV37 7GZ
Cardiogeni PLC is engaged in the development and commercialisation of a portfolio of novel cellular medicines for heart failure. The Company focuses on the development and commercialisation of novel cellular medicines targeting early- and mid-stage heart failure. Its strategic priority is to complete a pivotal Phase 2b/3 study and obtain first market approval for its product, CLXR-001, in a suitable jurisdiction, and then establish strategic funding and collaboration agreements to develop and commercialise the product in the US, EU, Japan, and other jurisdictions.